Novartis receives European approval for Cosentyx
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
The company reported lifetime high EBIDTA of Rs. 250 crores
The PP-based top and bottom webs are manufactured in a unique coextrusion process
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
The product is expected to be launched in June 2023
Subscribe To Our Newsletter & Stay Updated